More than a decade of Drugs to Watch
Our picks, from 2013 to the present.
In identifying our 2025 Drugs to Watch, we drew on the expertise of more than 160 Clarivate analysts and 11 integrated data sets spanning hundreds of drugs, diseases and markets and covering the whole of the innovation lifecycle.
| Drug Name | Company | Therapy Area | Year |
| COBENFY | Karuna Therapeutics | Schizophrenia and psychosis related to Alzheimer’s disease | 2025 |
| AWIQLI | Novo Nordisk A/S | Type 1 diabetes mellitus (T1DM), Type 2 diabetes mellitus (T2DM) | 2025 |
| CagriSema | Novo Nordisk A/S | Obesity, Type 2 diabetes mellitus (T2DM) | 2025 |
| EBGLYSS | Almirall, Eli Lilly and Co. | Atopic dermatitis | 2025 |
| Fitusiran | Alnylam Pharmaceuticals Inc., Sanofi SA | Hemophilia A, Hemophilia B | 2025 |
| GSK-3536819 | GlaxoSmithKline plc | Meningococcal disease | 2025 |
| IMDELLTRA | Amgen | Small-cell lung cancer (SCLC) | 2025 |
| mRESVIA | Moderna Therapeutics | Respiratory syncytial virus (RSV) | 2025 |
| SEL-212 | Cartesian Therapeutics Inc/Selecta Biosciences Inc, Sobi | Gout | 2025 |
| Vepdegestrant | Arvinas Inc, Pfizer Inc. | Breast cancer | 2025 |
| Zanzalintinib | Exelixis Inc | Colorectal cancer, Renal cell carcinoma, Squamous cell carcinoma of head and neck | 2025 |
| Zolbetuximab | Astellas Pharma Inc. | Gastric and gastroesophageal junction (GEJ) adenocarcinomas | 2024 |